Multi-state models for bleeding episodes and mortality in liver cirrhosis

Statistics in Medicine

Volumn 19, Issue 4, 2000, Pages 587-599

  Andersen, Per Kragh ^a   Esbjerg, Sille ^a   Sørensen, Thorkild I A ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b The Capital Region   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL;

CHRONIC LIVER DISEASE; CONFERENCE PAPER; DATA ANALYSIS; ESOPHAGUS VARICES BLEEDING; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MORTALITY; PROBABILITY; SCLEROTHERAPY; STATISTICAL MODEL; SURVIVAL TIME; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HEMORRHAGE; HUMANS; LIVER CIRRHOSIS; MALE; MODELS, BIOLOGICAL; MULTICENTER STUDIES; PROPORTIONAL HAZARDS MODELS; PROPRANOLOL; SCLEROTHERAPY;

EID: 0034728345     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0258(20000229)19:4<587::AID-SIM358>3.0.CO;2-0     Document Type: Conference Paper

References (16)

1. Kay R. A Markov model for analyzing cancer markers and disease states in survival studies. Biometrics 1986; 42:855-865.
2. Andersen PK. Multistate models in survival analysis: a study of nephropathy and mortality in diabetes. Statistics in Medicine 1998; 17:661-670.
3. Andersen PK, Hansen LS, Keiding N. Assessing the influence of reversible disease indicators on survival. Statistics in Medicine 1991; 10:1061-1067.
4. Hsieh FY, Crowley JJ, Tormey DC. Some test statistics for use in multi state survival analysis. Biometrika 1983; 70:111-119.
5. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. Wiley: New York, 1980.
6. Andersen PK, Borgan Ø, Gill RD, Keiding N. Statistical Models Based on Counting Processes. Springer: New York, 1993.
7. Klein JP, Keiding N, Copelan EA. Plotting summary predictions in multistate survival models: Probabilities of relapse and death in remission for bone marrow transplantation patients. Statistics in Medicine 1993; 12:2315-2332.
8. Lagakos SW. Using auxiliary variables for improved estimates of survival time. Biometrics 1977; 33:399-404.
9. PROVA Study Group. Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. Hepatology 1991; 14:1016-1024.
10. Thomsen BLT, Møller S, Sørensen TIA, The EVASP Group, Optimized analysis of recurrent bleeding and death in patients with cirrhosis and esophageal varices. Journal of Hepatology 1994; 21:367-375.
11. Thomsen BLT, Sørensen TIA, The EVASP Group. Analysis of the treatment effect on recurrent bleeding and death in patients with cirrhosis and esophageal varices. Multistage competing-risks model compared to conventional methods. Journal of Hepatology 1998; 28:107-114.
12. Cox DR. Regression models and life-tables (with discussion). Journal of the Royal Statistical Society, Series B 1972; 34:187-220.
13. Andersen PK, Bentzon MW, Klein JP. Estimating the survival function in the proportional hazards regression model: a study of the small sample size properties. Scandinavian Journal of Statistics 1996; 23:1-12.
14. Altman DG, Andersen PK. Bootstrap investigation of the stability of a Cox regression model. Statistics in Medicine 1989; 8:771-783.
15. SAS Institute Inc. SAS User's Guide: Statistics, Version 5 Edition. SAS Institute: Cary, North Carolina, 1985.
16. Pepe MS. Inference for events with dependent risks in multiple endpoint studies. Journal of the American Statistical Association 1991; 86:770-778.